Before today's market open, the Durham, NC-based biopharmaceutical company posted a net loss of 82 cents per share, wider than the loss of 73 cents per share that analysts were expecting.
Revenue for the period was $3.1 million, beating analysts' estimates of $2.68 million.
"We remain confident in the antiviral activity shown by brincidofovir, and its significant potential as a much-needed treatment option for patients with adenovirus and other DNA viral infections," said President and CEO M. Michelle Berrey in a statement.
Brincidofovir is the company's experimental antiviral drug for the treatment of DNA viruses, such as cytomegalovirus and adenovirus.
"We continue to move our intravenous formulation of brincidofovir toward clinical studies in the second half of 2016, and anticipate a lower risk of gastrointestinal side effects based on preclinical observations to date," Berrey added.
Separately, TheStreet Ratings Team has a "Sell" rating with a score of D on the stock.
This is driven by some concerns, which should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks covered.
The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: CMRX